Home » Topics » Disease categories and therapies » Immune

Immune
RSS

Spanish market introduction announced for antirejection MAb

March 15, 1999

BTG licenses anti-CD3 antibody to LeukoSite

March 15, 1999

FDA grants fast track designation for pneumococcal conjugate vaccine

March 12, 1999

Zenapax shows positive results in GVHD trial

March 10, 1999

North American Vaccine adds new product to R&D pipeline; U.S. patent issues

March 8, 1999

Licensing opportunity from BTG: fatty acid-peptide conjugates for use in vaccines

March 5, 1999

Epicoat technology granted U.S. patent protection

March 5, 1999

Roche obtains European marketing approval for transplant drug

March 4, 1999

Novel vaccine technology available for licensing from BTG

March 4, 1999

Praxis purchases intellectual property allowing development of antirejection drug

March 4, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....